non-small cell lung cancer

#ESMO20: AstraZeneca burnishes Tagrisso's adjuvant NSCLC profile with 'unprecedented' reduction in brain mets. Can they win over skeptics?
#ESMO20: AstraZeneca burnishes Tagrisso's adjuvant NSCLC profile with 'unprecedented' reduction in brain mets. Can they win over skeptics?
Endpoints
AstraZeneca
Tagrisso
non-small cell lung cancer
ESMO
Flag link:
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
Xconomy
Blueprint Medicines
FDA
Gavreto
pralsetinib
cancer
RET
non-small cell lung cancer
Flag link:
Turning Point touts positive pivotal NSCLC data, hints at even faster OK — but can it beat Pfizer and Roche?
Turning Point touts positive pivotal NSCLC data, hints at even faster OK — but can it beat Pfizer and Roche?
Endpoints
Turning Point Therapeutics
repotrectinib
non-small cell lung cancer
clinical trials
Pfizer
Roche
Flag link:
Deaths from the most common lung cancer are falling fast, hinting at the impact of improved treatment
Deaths from the most common lung cancer are falling fast, hinting at the impact of improved treatment
Stat
lung cancer
non-small cell lung cancer
targeted therapeutics
Flag link:
WCLC: Lilly, Innovent tout Tyvyt front-line lung cancer win. Can it challenge Merck’s Keytruda?
WCLC: Lilly, Innovent tout Tyvyt front-line lung cancer win. Can it challenge Merck’s Keytruda?
Fierce Pharma
Eli Lilly
Innovent Biologics
China
non-small cell lung cancer
Tyvyt
Merck
Keytruda
Flag link:
Daiichi Sankyo, AstraZeneca collaborate to evaluate patritumab deruxtecan in combination with TAGRISSO in EGFR-mutated NSCLC
Daiichi Sankyo, AstraZeneca collaborate to evaluate patritumab deruxtecan in combination with TAGRISSO in EGFR-mutated NSCLC
Pharmaceutical Business Review
Daiichi Sankyo
AstraZeneca
patritumab deruxtecan
Tagrisso
non-small cell lung cancer
clinical trials
Flag link:
Elevation Oncology launches with $32.5 million Series A, gives new life to former Merrimack program
Elevation Oncology launches with $32.5 million Series A, gives new life to former Merrimack program
Endpoints
Elevation Oncology
Merrimack
seribantumab
non-small cell lung cancer
Flag link:
NovoCure, Merck Team Up on Phase II Lung Cancer Trial
NovoCure, Merck Team Up on Phase II Lung Cancer Trial
BioSpace
Merck
Novocure
clinical trials
tumor treating fields
Keytruda
non-small cell lung cancer
Flag link:
Daiichi Sankyo and Thermo Fisher Partner on Companion Diagnostic Device for NSCLC
Daiichi Sankyo and Thermo Fisher Partner on Companion Diagnostic Device for NSCLC
BioSpace
Daiichi Sankyo
Thermo Fisher
companion diagnostics
diagnostics
non-small cell lung cancer
Flag link:
NICE backs funding for Roche’s lung cancer drug after price cut
NICE backs funding for Roche’s lung cancer drug after price cut
Pharmaforum
NICE
Roche
Rozlytrek
non-small cell lung cancer
Flag link:
Marketing Lilly's Cyramza, after split decision from FDA advisers, wins first-line lung cancer nod
Marketing Lilly's Cyramza, after split decision from FDA advisers, wins first-line lung cancer nod
Fierce Pharma
Eli Lilly
Cyramza
FDA
non-small cell lung cancer
Flag link:
Ahead of ASCO, Bristol Myers Squibb Announces Results for Three Clinical Trials
Ahead of ASCO, Bristol Myers Squibb Announces Results for Three Clinical Trials
BioSpace
Bristol-Myers Squibb
Opdivo
Yervoy
non-small cell lung cancer
ide-cel
Multiple Myeloma
Bluebird Bio
ASCO 2020
Flag link:
Novartis Drug Wins FDA Approval for Lung Cancers With Specific Mutation
Novartis Drug Wins FDA Approval for Lung Cancers With Specific Mutation
Xconomy
Novartis
Tabectra
FDA
non-small cell lung cancer
capmatinib
Flag link:
AstraZeneca stops lung cancer trial early, after star drug Tagrisso induces 'overwhelming' efficacy
AstraZeneca stops lung cancer trial early, after star drug Tagrisso induces 'overwhelming' efficacy
Endpoints
AstraZeneca
Tagrisso
clinical trials
non-small cell lung cancer
Flag link:
BMS' Opdivo gets another lung cancer shot as FDA, EMA accept chemo combo filings
BMS' Opdivo gets another lung cancer shot as FDA, EMA accept chemo combo filings
Fierce Pharma
Bristol-Myers Squibb
Opdivo
Yervoy
non-small cell lung cancer
FDA
Europe
priority review
EMA
Flag link:
In two-man race with Novartis, Merck scores first regulatory approval for targeted lung cancer drug
In two-man race with Novartis, Merck scores first regulatory approval for targeted lung cancer drug
Endpoints
Novartis
Merck KGaA
Japan
tepotinib
non-small cell lung cancer
Flag link:
Lilly’s Cyramza closer to first-line lung cancer use after ODAC verdict
Lilly’s Cyramza closer to first-line lung cancer use after ODAC verdict
Pharmaforum
Eli Lilly
Cyramza
non-small cell lung cancer
FDA
advisory panels
Flag link:
Takeda’s ALUNBRIG gets FDA priority review for expanded indication in NSCLC
Takeda’s ALUNBRIG gets FDA priority review for expanded indication in NSCLC
Pharmaceutical Business Review
Takeda
Alunbrig
brigatinib
FDA
priority review
non-small cell lung cancer
Flag link:
FDA Grants Priority Review to Roche's Lung Cancer Drug Tecentriq
FDA Grants Priority Review to Roche's Lung Cancer Drug Tecentriq
Motley Fool
Roche
FDA
priority review
Tecentriq
non-squamous non-small cell lung cancer
non-small cell lung cancer
Flag link:
Novartis nabs priority review for a blockbuster-to-be aimed at NSCLC niche — delighting Incyte execs
Novartis nabs priority review for a blockbuster-to-be aimed at NSCLC niche — delighting Incyte execs
Endpoints
Incyte
Novartis
FDA
capmatinib
prioirty review
non-small cell lung cancer
Flag link:

Pages